Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity Study of VLA15 in Healthy Pediatric and Adult Subjects
NCT04801420Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of VLA15 in Lyme borreliosis, sponsored by Pfizer. Started Mar 2021; status: completed.
02
Drugs
VLA15
03
Conditions
Lyme borreliosis
Beyond the preview
Go deeper on NCT04801420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04801420.